Ekrem AKDENİZ, Sevda AKDENİZ, Ebru KELSAKA, Fuat GÜLDOĞUŞ, YAKUP BOSTANCI

Ağrı şikayeti ile algoloji polikliniğine başvuran prostat kanserli olguların retrospektif değerlendirilmesi

Amaç: Kronik ağrı şikayeti ile ağrı polikliniğine başvuran prostat kanserli hastaların ağrı tipleri ve tedavi sonuçlarının retrospektif değerlendirilmesidir.Gereç ve Yöntemler: Ocak 2000 - Aralık 2010 tarihleri arasında Ondokuz Mayıs Üniversitesi Tıp Fakültesi Hastanesi Algoloji Bilim Dalı polikliniğine ağrı nedeni ile başvuran prostat kanseri tanısı almış olan olgular incelendi. Olguların sosyodemografik özellikleri, ağrı durumları ve uygulanan tedaviler hasta dosyalarından retrospektif olarak analiz edildi. Hastaların tamamına Dünya Sağlık Örgütü’nün WHO önerdiği basamak tedavisi uygulandı. Farmakolojik tedaviden fayda görmeyen hastalara ise invaziv girişimler uygulandı. Bulgular: Prostat kanserli hastaların yaş ortalaması 73.6±8.4 yıl idi. Hastaların %16.9’u n=46 kendi isteği ile başvururken, %83.1’i cer patients was 73.6 ± 8.4 year. While 16.9% of n=226 üroloji polikliniğinden tarafımıza refethe patients n=46 presented by their own will, re edilmişti. Hastaların %91.2’sinde n=248 kemik metastazı varken %8.8’inde n=24 metastaz izlenmedi. Hastaların %87.1’ine n=237 farmakolojik tedavi verilirken %12.9’una n=35 farmakolojik + invaziv tedavi verildiği öğrenildi. İnvaziv girişim yapılan hastaların %96.9’una n=31 epidural kateter uygulanmıştı. Sonuç: İleri evre prostat kanseri, ağrının en çok eşlik ettiği kanserlerin başında gelir. Ağrının palyasyonu hastalığın morbiditesi ile doğrudan ilgilidir. Kansere eşlik eden ağrının multidisipliner yöntemlerle tedavi edilmesi gerekmektedir

Anahtar Kelimeler:

Ağrı, ağrı tedavisi, prostat kanseri

Retrospective analysis of prostate cancer patients who complain with pain and admitted to algology department

Objective: Evaluating the types of pain and the results of treatment as retrospectively in patients with prostate cancer who apply to the Algology department with the complain of chronic pain.Material and Methods: Patients presenting to the Ondokuz Mayis University Faculty of Medicine, Department of Algology with pain and diagnosed with prostate cancer between January 2000 and December 2010 were investigated. The sociodemographic characteristics, pain status and the treatments administered were evaluated retrospectively from the patient files. All the patients were administered the WHO World Health Organization analgesic ladder; patients who could not benefit from the pharmacological treatment were detected to receive invasive procedures Figure 1 .Results: The mean age of the prostate can

Keywords:

Pain, treatment of pain, prostate cancer,

PDF

___

Caraceni A, Portenoy RK. An international survey of can- cer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999 Sep;82(3):263-74.
Coleman RE. Metastatic bone disease: clinical features, pat- hophysiology and treatment strategies. Cancer Treat Rev. 2001 Jun;27(3):165-76.
Büyükalpelli R. Prostat kanserinde ağrı ve tedavisi. Üroon- koloji Bülteni 2009;1:7-13.
Kaya E, Feuer D. Prostate cancer: palliative care and pain re- lief. Prostate Cancer Prostatic Dis. 2004;7(4):311-5.
Kuzeyli Yildirim Y, Uyar M, Fadillioglu C. Cancer pain and its influence on quality of life. Agri. 2005 Oct;17(4):17-22.
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96.
Eser S, Olcayto E, Karakılınç H ve ark. Nüfus Tabanlı Kan- ser Kayıt Merkezleri Veri Havuzu: Sekiz İl 2004-2006 De- ğerlendirilmesi. http://www.kanser.gov.tr/folders/file/8iL- 2006-SON.
Bader P, Echtle D, Fonteyne V, et al. Prostate cancer pain management: EAU guidelines on pain management. World J Urol. 2012 Feb 9.
Nakamura T, Katou H, Makino T, Okugi H, Okazaki H. Symptoms of prostate cancer that required treatment in the terminal stage for two years. Hinyokika Kiyo. 2010 Jan;56(1):11-5.
Saylor PJ, Smith MR. Bone health and prostate cancer. Pros- tate Cancer Prostatic Dis. 2010 Mar;13(1):20-7.
Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997 Jan;69(1-2):1-18.
Ashburn MA, Lipman AG. Management of pain in the can- cer patient. Anesth Analg. 1993 Feb;76(2):402-16.
Mercadante S, Fulfaro F. Management of painful bone me- tastases. Curr Opin Oncol. 2007 Jul;19(4):308-14.
Vengalil S, O’Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care. 2012 Sep;6(3):310-5.
Goyal J, Antonarakis ES. Bone-targeting radiopharmaceuti- cals for the treatment of prostate cancer with bone metasta- ses. Cancer Lett. 2012 Oct 28;323(2):135-46.
Kurata T, Nakagawa K. Efficacy and safety of denosumab for the treatment of bone metastases in patients with advan- ced cancer. Jpn J Clin Oncol. 2012 Aug;42(8):663-9.
Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA. Evidence-based standards for cancer pain manage- ment. J Clin Oncol. 2008 Aug 10;26(23):3879-85.
Hartsell WF, Scott CB, Bruner DW, et al. Randomized tri- al of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005 Jun 1;97(11):798-804.
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007 Aug;28(8):623-30.
Diel IJ, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated os- teonecrosis of the jaw: Is there a diverse relationship of ami- no- and non-aminobisphosphonates? Crit Rev Oncol He- matol. 2007 Dec;64(3):198-207.
Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol. 2001 Jan;165(1):136-40.
Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004;9(5):571-91.
Reid CM, Gooberman-Hill R, Hanks GW. Opioid analge- sics for cancer pain: symptom control for the living or com- fort for the dying? A qualitative study to investigate the fac- tors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol. 2008 Jan;19(1):44-8.
Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser. 1990;804:1-75.
Pharo GH, Zhou L. Pharmacologic management of can- cer pain. J Am Osteopath Assoc. 2005 Nov;105(11 Suppl 5):S21-8.
Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment follo- wing WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001 Sep;93(3):247-57.
Du Pen SL, Kharasch ED, Williams A, et al. Chronic epidu- ral bupivacaine-opioid infusion in intractable cancer pain. Pain. 1992 Jun;49(3):293-300.
Jeon YS, Lee JA, Choi JW, et al. Efficacy of epidural analge- sia in patients with cancer pain: a retrospective observatio- nal study. Yonsei Med J. 2012 May;53(3):649-53.
Ballantyne JC, Carwood CM. Comparative efficacy of epi- dural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev. 2005(1):CD005178.
Mercadante S. Controversies over spinal treatment in advanced cancer patients. Support Care Cancer. 1998 Nov;6(6):495-502.
Uslu R, Uyar M. Cancer and palliative care. Agri. 2005 Jul;17(3):5-10.